Aton Ra Partners Axonics, Inc. Transaction History

Aton Ra Partners

$50.1 Million
Q4 2023

A detailed history of Aton Ra Partners transactions in Axonics, Inc. stock. As of the latest transaction made, Aton Ra Partners holds 8,097 shares of AXNX stock, worth $574,725. This represents 1.0% of its overall portfolio holdings.

Number of Shares

8,097

Previous 8,833 8.33%

Holding current value

$574,725

Previous $495,000 1.62%

% of portfolio

1.0%

Previous 1.04%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$49.38 - $63.75 $36,343 - $46,920	-736 Reduced 8.33%	8,097 $503,000
Q3 2023 Oct 25, 2023	SELL	$48.64 - $62.51 $14,640 - $18,815	-301 Reduced 3.3%	8,833 $495,000
Q2 2023 Jul 18, 2023	SELL	$47.99 - $60.21 $72,464 - $90,917	-1,510 Reduced 14.19%	9,134 $460,000
Q1 2023 May 05, 2023	SELL	$52.6 - $67.34 $78,742 - $100,807	-1,497 Reduced 12.33%	10,644 $580,000
Q4 2022 Feb 02, 2023	SELL	$59.56 - $76.6 $285,292 - $366,914	-4,790 Reduced 28.29%	12,141 $759,000
Q3 2022 Nov 14, 2022	SELL	$57.96 - $78.12 $202,280 - $272,638	-3,490 Reduced 17.09%	16,931 $1.19 Million
Q2 2022 Aug 15, 2022	SELL	$39.5 - $64.42 $69,796 - $113,830	-1,767 Reduced 7.96%	20,421 $1.16 Million
Q1 2022 May 16, 2022	SELL	$43.74 - $62.76 $162,187 - $232,714	-3,708 Reduced 14.32%	22,188 $1.39 Million
Q4 2021 Feb 14, 2022	BUY	$50.01 - $73.35 $64,462 - $94,548	1,289 Added 5.24%	25,896 $1.45 Million
Q3 2021 Nov 15, 2021	BUY	$59.21 - $78.66 $200,662 - $266,578	3,389 Added 15.97%	24,607 $1.6 Million
Q2 2021 Aug 12, 2021	SELL	$51.39 - $66.9 $54,576 - $71,047	-1,062 Reduced 4.77%	21,218 $1.35 Million
Q1 2021 May 17, 2021	BUY	$49.14 - $59.89 $1.09 Million - $1.33 Million	22,280 New	22,280 $1.33 Million

Others Institutions Holding AXNX

# of Institutions

Shares Held

10.1M

Call Options Held

5.2K

Put Options Held

58.3K

View Full List

About Axonics, Inc.

Ticker AXNX
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 49,123,600
Market Cap $3.49B
Description
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...

More about AXNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aton Ra Partners, based on Form 13F filings with the SEC.

News

Stay updated on Aton Ra Partners with notifications on news.

Account